COVID-19 Bivalent Boosters Authorized for Use
The CDC Advisory Committee on Immunization Practices (ACIP) has voted to recommend both the Moderna COVID-19 bivalent booster (ages 18+) and the Pfizer-BioNTech bivalent booster (ages 12+) for use this fall.
Additionally, monovalent COVID-19 vaccines are NO LONGER authorized as booster doses for individuals 12 years of age and older.
Please review the COVID-19 vaccine EUA fact sheets for the most up-to-date information on each vaccine.
Moderna Bivalent Booster
The Moderna Bivalent Booster (ages 18+) (NDC 80777-0282-99) is available to order in ASIIS. This product has a blue cap with a gray border on the label. Each vial contains 5 doses (0.5mL dose size).
This product follows the same storage guidelines as the Moderna products we are used to. This product should be administered as a single booster dose to patients at least 2 months after the patient has completed primary vaccination or has received the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine.
Pfizer-BioNTech Bivalent Booster
The Pfizer Bivalent Booster (ages 12+) (NDC 59267-0304-02) is available to order in ASIIS. This product looks identical to the Pfizer gray cap product used for primary series in ages 12+. Please ensure you are double-checking the NDCs and packaging labels prior to administration. Each vial contains 6 doses (0.3mL dose size).
This product follows the same storage guidelines as the Pfizer gray, orange, and maroon cap products we are used to. This product should be administered as a single booster dose to patients at least 2 months after the patient has completed primary vaccination or has received the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine.
Resources
COVID-19 Vaccine Presentations Available to Order in ASIIS
Moderna BIVALENT BOOSTER Ages 18+
Moderna FDA EUA for Bivalent Booster
Pfizer-BioNTech BIVALENT BOOSTER Ages 12+
Pfizer-BioNTech FDA EUA for Bivalent Booster
CDC’s Interim Clinical Considerations
|
